Purple Biotech (PPBT) Profit After Tax (2014 - 2026)

Purple Biotech (PPBT) has reported Profit After Tax for 13 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 67.05% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $27.7 million (up 310.75% YoY), while the FY2025 annual figure was -$26.5 million, down 263.95% from the prior year.
• Profit After Tax eased to $2.2 million in Q1 2026 per PPBT's latest filing, from $23.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $23.2 million in Q4 2025 and bottomed at -$4.9 million in Q4 2023.
• Historically, Profit After Tax has averaged $4.1 million across 5 years, with a median of $3.6 million in 2022.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 180.41% — and 2025, when it jumped 3580.92%.
• Purple Biotech's Profit After Tax stood at $6.0 million in 2022, then sank by 180.41% to -$4.9 million in 2023, then jumped by 112.95% to $629000.0 in 2024, then surged by 3580.92% to $23.2 million in 2025, then sank by 90.5% to $2.2 million in 2026.
• Business Quant data shows PPBT's Profit After Tax at $2.2 million in Q1 2026, $23.2 million in Q4 2025, and $1.2 million in Q3 2025.